摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-5-(4-甲氧基-苄氧基)-吡啶 | 552332-65-7

中文名称
3-氯-5-(4-甲氧基-苄氧基)-吡啶
中文别名
——
英文名称
3-Chloro-5-(4-methoxy-benzyloxy)-pyridine
英文别名
3-chloro-5-[(4-methoxyphenyl)methoxy]pyridine
3-氯-5-(4-甲氧基-苄氧基)-吡啶化学式
CAS
552332-65-7
化学式
C13H12ClNO2
mdl
——
分子量
249.697
InChiKey
LZEDAHOLDLSSMO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    373.2±32.0 °C(Predicted)
  • 密度:
    1.228±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氯-5-(4-甲氧基-苄氧基)-吡啶三苯基膦三氟乙酸lithium diisopropyl amide偶氮二甲酸二乙酯 作用下, 以 四氢呋喃 为溶剂, 生成 [(S)-1-(5-Chloro-4-methyl-pyridin-3-yloxymethyl)-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester
    参考文献:
    名称:
    Isoquinoline–pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity
    摘要:
    The structure-activity relationships of a series of isoquinoline-pyridine-based protein kinase B/Akt antagonists have been investigated in an effort to improve the major short-comings of the lead compound 3, including poor pharmacokinetic profiles in several species (e.g., mouse iv t(1/2) = 0.3 h, po F= 0%). Chlorination at C-1 position of the isoquinoline improved its pharmacokinetic property in mice (iv t(1/2) = 5.0 h, po F = 51%) but resulted in > 500-fold drop in potency. In a mouse MiaPaCa-2 xenograft model, an amino analog 10y significantly slowed the tumor growth, however was accompanied by toxicity. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.03.041
  • 作为产物:
    描述:
    5-氯-3-羟基吡啶4-甲氧基苄醇三苯基膦偶氮二甲酸二乙酯 作用下, 以 四氢呋喃乙酸乙酯 为溶剂, 以53%的产率得到3-氯-5-(4-甲氧基-苄氧基)-吡啶
    参考文献:
    名称:
    Kinase inhibitors
    摘要:
    具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。
    公开号:
    US20030187026A1
点击查看最新优质反应信息

文献信息

  • Kinase inhibitors
    申请人:——
    公开号:US20030187026A1
    公开(公告)日:2003-10-02
    Compounds having the formula 1 are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
    具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。
  • 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER
    申请人:Abbott Laboratories
    公开号:EP1463505A2
    公开(公告)日:2004-10-06
  • US6831175B2
    申请人:——
    公开号:US6831175B2
    公开(公告)日:2004-12-14
  • [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE
    申请人:ABBOTT LAB
    公开号:WO2003051366A2
    公开(公告)日:2003-06-26
    Compounds having the formula (I), are useful for inhibiting protein kinases and for the treatment of cancer. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
  • Isoquinoline–pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity
    作者:Gui-Dong Zhu、Jianchun Gong、Akiyo Claiborne、Keith W. Woods、Viraj B. Gandhi、Sheela Thomas、Yan Luo、Xuesong Liu、Yan Shi、Ran Guan、Shayna R. Magnone、Vered Klinghofer、Eric F. Johnson、Jennifer Bouska、Alexander Shoemaker、Anatol Oleksijew、Vincent S. Stoll、Ron De Jong、Tilman Oltersdorf、Qun Li、Saul H. Rosenberg、Vincent L. Giranda
    DOI:10.1016/j.bmcl.2006.03.041
    日期:2006.6
    The structure-activity relationships of a series of isoquinoline-pyridine-based protein kinase B/Akt antagonists have been investigated in an effort to improve the major short-comings of the lead compound 3, including poor pharmacokinetic profiles in several species (e.g., mouse iv t(1/2) = 0.3 h, po F= 0%). Chlorination at C-1 position of the isoquinoline improved its pharmacokinetic property in mice (iv t(1/2) = 5.0 h, po F = 51%) but resulted in > 500-fold drop in potency. In a mouse MiaPaCa-2 xenograft model, an amino analog 10y significantly slowed the tumor growth, however was accompanied by toxicity. (c) 2006 Elsevier Ltd. All rights reserved.
查看更多